Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06927739

Focused Orticumab Research for Treating Inflammation in Coronary Arteries (FORTIFY)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants With Prior Myocardial Infarction Who Have Elevated Coronary Inflammation Based on FAI Score Assessed by CCTA

Sponsor: Abcentra

Conditions Acute Coronary Syndromes Atherosclerotic Coronary Vascular Disease Coronary Arterial Disease (CAD) Heart Disease Inflammation Myocardial Infarct

Interventions Orticumab Placebo

Updated 3 times since 2025 Last updated: Jan 24, 2026 Started: Aug 11, 2025 Primary completion: Feb 8, 2027 Completion: Jun 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Acute Coronary Syndromes and Atherosclerotic Coronary Vascular Disease, this trial is actively recruiting participants. The trial is conducted by Abcentra and has accumulated 3 data snapshots since 2025. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2025 — Nov 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abcentra

Data source: Abcentra

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baia Mare, Romania , Baltimore, United States , Bath, United Kingdom , Boca Raton, United States , Brescia, Italy , Brno, Czechia , Budapest, Hungary , Caserta, Italy , Córdoba, Spain , Danderyd, Sweden and 27 more locations